Mitchell Glass
Directeur/Membre du Conseil chez MYMD PHARMACEUTICALS, INC.
Profil
Mitchell Glass is currently the Chief Executive Officer & Director at Chronic Airway Therapeutics and the Chairman at Accolade Pharma LLC.
He is also a Director at Orphagenix, Inc., Avatar Biotechnologies LLC, and MyMD Pharmaceuticals, Inc. In the past, he served as the Chief Executive Officer at Aqumen Biopharmaceuticals KK and Aqumen Biopharmaceuticals NA, Inc. He was also the Director & Vice President at GlaxoSmithKline LLC and the Executive Director & Chief Medical Officer at Invion Ltd.
Additionally, he held positions as the Chief Medical Officer & VP-Regulatory Affairs at AtheroGenics, Inc. and the Chief Scientific Officer at University City Science Center.
He has also worked as a Principal at the University of Pennsylvania, AstraZeneca, Inc., and Inverseon, Inc. Dr. Glass obtained his undergraduate and doctorate degrees from The University of Chicago in 1973 and 1977, respectively.
Postes actifs de Mitchell Glass
| Sociétés | Poste | Début |
|---|---|---|
| MYMD PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 08/04/2024 |
| Orphagenix, Inc. | Directeur/Membre du Conseil | 13/04/2010 |
| Avatar Biotechnologies LLC | Directeur/Membre du Conseil | 13/04/2010 |
Chronic Airway Therapeutics
 Chronic Airway Therapeutics BiotechnologyHealth Technology Chronic Airway Therapeutics develops treatments for chronic respiratory diseases. The private company is based in Kew East, Australia. The CEO of the Australian company is Mitchell Glass. | Directeur Général | - |
Accolade Pharma LLC
 Accolade Pharma LLC Pharmaceuticals: MajorHealth Technology Accolade Pharma LLC is a pharmaceutical company that specializes in developing topical formulations and devices for the active ingredient of Accolate® (zafirlukast) to treat allergic inflammation. The private company is based in Wilmington, DE. Leukotriene antagonists modify allergic responses by blocking leukotrienes, which prevents or decreases symptoms of acute inflammation such as wheezing, sneezing, itching, redness, and swelling. The company was founded in 2012 by G. John Mohr, who has been the CEO since 2012. | Président | - |
Anciens postes connus de Mitchell Glass
| Sociétés | Poste | Fin |
|---|---|---|
| INVION LIMITED | Directeur/Membre du Conseil | 12/02/2019 |
Inverseon, Inc.
 Inverseon, Inc. Pharmaceuticals: MajorHealth Technology Inverseon, Inc. is a private company developing a re-profiled beta blocker for the treatment of asthma and COPD. Inverseon’s scientific approach, “Paradoxical Pharmacology”, is based on observations that chronic effects of inverse agonist drugs are completely opposite to their acute effects. A similar paradigm shift occurred in the late 1990’s with the approval of the first beta blocker for congestive heart failure, a disease state where the drug was also originally contraindicated. Inverseon’s scientific founder, Professor Richard Bond, identified the mechanism of action as inverse agonism at the beta adrenergic receptor and hypothesized that this observation represented a general pharmacological phenomenon and identified asthma as another disease to target. To date, the company has achieved a number of important milestones: completing two open-label Phase 2a studies demonstrating a dose-response, a comment in The Lancet in 2009 highlighting the published human clinical trial, and 2009 issuance of their first U.S. patent. | Corporate Officer/Principal | 01/09/2012 |
| Aqumen Biopharmaceuticals NA, Inc. | President | 02/01/2008 |
University City Science Center
 University City Science Center Investment Trusts/Mutual FundsMiscellaneous University City Science Center provides physical space, resources and other support to the community. The company was founded in 1963 and is headquartered in Philadelphia, PA. | Directeur Technique/Scientifique/R&D | 02/01/2006 |
| ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Mitchell Glass
| The University of Chicago | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| INVION LIMITED | Health Technology |
| MYMD PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 11 |
|---|---|
AtheroGenics, Inc.
 AtheroGenics, Inc. Pharmaceuticals: MajorHealth Technology AtheroGenics is a pharmaceutical company focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, such as atherosclerosis, asthma and arthritis. | Health Technology |
| Orphagenix, Inc. | |
University City Science Center
University City Science Center Investment Trusts/Mutual FundsMiscellaneous University City Science Center provides physical space, resources and other support to the community. The company was founded in 1963 and is headquartered in Philadelphia, PA. | Miscellaneous |
AstraZeneca, Inc.
 AstraZeneca, Inc. BiotechnologyHealth Technology Part of AstraZeneca PLC, AstraZeneca, Inc. manufactures vaccines. | Health Technology |
Aqumen Biopharmaceuticals KK
 Aqumen Biopharmaceuticals KK Pharmaceuticals: MajorHealth Technology Aqumen Biopharmaceuticals KK is a holding company that provides research and development of therapeutic medicines for macular degeneration. It also develops therapeutics for diabetic retinopathy, diabetic nephropathy, adjuvants for ophthalmic surgery, and intraocular drug delivery systems. The firm's products encompass the ILM-Blue and the MembraneBlue-Dual. The company was founded by Kimihiko Fujisawa and Tadahisa Kagimoto on April 11, 2005 and is headquartered in Fukuoka, Japan. | Health Technology |
Inverseon, Inc.
Inverseon, Inc. Pharmaceuticals: MajorHealth Technology Inverseon, Inc. is a private company developing a re-profiled beta blocker for the treatment of asthma and COPD. Inverseon’s scientific approach, “Paradoxical Pharmacology”, is based on observations that chronic effects of inverse agonist drugs are completely opposite to their acute effects. A similar paradigm shift occurred in the late 1990’s with the approval of the first beta blocker for congestive heart failure, a disease state where the drug was also originally contraindicated. Inverseon’s scientific founder, Professor Richard Bond, identified the mechanism of action as inverse agonism at the beta adrenergic receptor and hypothesized that this observation represented a general pharmacological phenomenon and identified asthma as another disease to target. To date, the company has achieved a number of important milestones: completing two open-label Phase 2a studies demonstrating a dose-response, a comment in The Lancet in 2009 highlighting the published human clinical trial, and 2009 issuance of their first U.S. patent. | Health Technology |
GlaxoSmithKline LLC
 GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology GlaxoSmithKline LLC engages in discovering, developing, and delivering medicines, vaccines, and other healthcare products. It offers prescription medicines that treat various diseases, including cancer, HIV/AIDS, depression, diabetes, high blood pressure, herpes, asthma, migraine, and heart diseases, as well as stomach and skin problems, infections, and flu. It also provides vaccines for children and adults; and over-the-counter products. The company was founded in 1929 and is headquartered in Philadelphia, PA. | Health Technology |
| Aqumen Biopharmaceuticals NA, Inc. | |
| Avatar Biotechnologies LLC | |
Accolade Pharma LLC
Accolade Pharma LLC Pharmaceuticals: MajorHealth Technology Accolade Pharma LLC is a pharmaceutical company that specializes in developing topical formulations and devices for the active ingredient of Accolate® (zafirlukast) to treat allergic inflammation. The private company is based in Wilmington, DE. Leukotriene antagonists modify allergic responses by blocking leukotrienes, which prevents or decreases symptoms of acute inflammation such as wheezing, sneezing, itching, redness, and swelling. The company was founded in 2012 by G. John Mohr, who has been the CEO since 2012. | Health Technology |
Chronic Airway Therapeutics
Chronic Airway Therapeutics BiotechnologyHealth Technology Chronic Airway Therapeutics develops treatments for chronic respiratory diseases. The private company is based in Kew East, Australia. The CEO of the Australian company is Mitchell Glass. | Health Technology |
